Tc-99m-Tilmanocept Imaging for Diabetic Kidney Disease
CH
Overseen ByCarl Hoh, MD
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: University of California, San Diego
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Trial Summary
What is the purpose of this trial?
This proposal will use kidney SPECT/CT of Tc-99m-tilmanocept to evaluate the mesangial changes seen in diabetics across the spectrum of kidney disease as well as persons with hypertensive kidney disease, the next most common cause of kidney disease in patients with diabetes. We aim to demonstrate that these different disease types and stages can be differentiated with Tc-99m-tilmanocept SPECT/CT and can thus be used for future trials evaluating early diagnosis and treatment of diabetic nephropathy.
Research Team
CH
Carl Hoh, MD
Principal Investigator
UC San Diego Medical Center
Eligibility Criteria
Adults over 18 with kidney disease, specifically diabetic or hypertensive kidney disease, can join this trial. They must consent to the study and not be pregnant or trying to conceive. Participants should have a stable health status (ECOG Grade 0-2) and a BMI between 18-49.9 kg/m2. Exclusions include recent drug/alcohol abuse, high radiation exposure, participation in other trials within 3 months, significant allergies to dextran, certain medication use prior to the trial start date, poor vein access for injections.Inclusion Criteria
I am 18 years old or older.
I can take care of myself and am up and about more than half of my waking hours.
The patient has provided written informed consent with HIPAA (Health Insurance Portability and Accountability Act) authorization before the initiation of any study-related procedures.
See 3 more
Exclusion Criteria
The subject has a history of significant hypersensitivity, intolerance, or allergy to dextran or modified forms of dextran; unless approved by the Investigator.
I have difficulty with needle insertions due to poor vein access.
The patient is pregnant or lactating.
See 12 more
Treatment Details
Interventions
- Tc-99m-Tilmanocept
Trial OverviewThe trial is testing Tc-99m-Tilmanocept using SPECT/CT imaging to detect mesangial changes in kidneys affected by diabetes or hypertension. The goal is to see if this method can differentiate stages of kidney disease and help diagnose diabetic nephropathy early on.
Participant Groups
3Treatment groups
Active Control
Group I: Tilmanocept Dose - 0.20 mgActive Control1 Intervention
Group II: Tilmanocept Dose - 0.40 mgActive Control1 Intervention
Group III: Tilmanocept Dose - 0.050 mgActive Control1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Diego
Lead Sponsor
Trials
1,215
Recruited
1,593,000+
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.